<DOC>
	<DOC>NCT02438007</DOC>
	<brief_summary>The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).</brief_summary>
	<brief_title>A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Progressive metastatic (M1) disease on androgen deprivation therapy Detectable ARV7 from circulating tumors (CTCs) ECOG performance status 0 or 1 Prior treatment with second generation antiandrogens (e.g. abiraterone, enzalutamide) Prior treatment with chemotherapy for CRPC</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>